Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $178.71

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus rating of “Moderate Buy” from the twenty-two analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nineteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $178.71.

A number of analysts recently commented on SRPT shares. Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Evercore ISI cut their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday. Finally, Piper Sandler cut their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. American Century Companies Inc. lifted its holdings in shares of Sarepta Therapeutics by 14.1% during the 2nd quarter. American Century Companies Inc. now owns 7,184 shares of the biotechnology company’s stock worth $1,135,000 after acquiring an additional 889 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Sarepta Therapeutics by 13.9% during the second quarter. Dimensional Fund Advisors LP now owns 255,396 shares of the biotechnology company’s stock valued at $40,353,000 after purchasing an additional 31,105 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Sarepta Therapeutics by 56.4% in the 2nd quarter. ProShare Advisors LLC now owns 10,286 shares of the biotechnology company’s stock valued at $1,625,000 after purchasing an additional 3,708 shares during the period. Evergreen Capital Management LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $209,000. Finally, Marshall Wace LLP boosted its stake in Sarepta Therapeutics by 1,196.3% in the 2nd quarter. Marshall Wace LLP now owns 43,335 shares of the biotechnology company’s stock valued at $6,847,000 after buying an additional 39,992 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $113.72 on Friday. The firm has a market capitalization of $10.86 billion, a PE ratio of 90.98 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25. The company’s 50 day simple moving average is $122.80 and its 200 day simple moving average is $127.08.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.